Board expansion Burst Diagnostics recently added two new directors to its board, signaling increased governance, credibility, and strategic guidance. This presents an opportunity to align engagement with the board on long-term partnerships, potential funding rounds, and strategic collaborations in point-of-need testing.

Point-of-need focus The company specializes in at-home and point-of-care diagnostics with a rapid, low-cost, easy-to-use format. This opens sales opportunities with retailers, clinics, urgent care networks, and consumer health channels seeking convenient, lab-quality performance in field settings.

Custom assay services Burst offers custom assay development to tailor analytes, samples, and use cases, powered by the CaDI platform. Target partnerships with pharmaceutical firms, CROs, and healthcare device integrators who need rapid assay customization and scalable production.

Growing revenue Current revenue range indicates a small-to-mid-market footprint with room to scale. Sales efforts can focus on multi-site deployments, recurring services for assay development, and expanded production capabilities for larger healthcare networks.

Strategic partnerships The mix of in-house product development and client-focused services suggests a viable path for channel partnerships with medical device manufacturers, diagnostics distributors, and healthcare technology integrators seeking to augment point-of-need testing portfolios.